Indivior Cuts Suboxone Buyers $30M Deal In Antitrust MDL
Indivior Inc. and the class of end payors who accused it of monopolizing the market on Suboxone, an opioid addiction treatment, have agreed to resolve their dispute in a $30 million...To view the full article, register now.
Already a subscriber? Click here to view full article